Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Tenax Therapeutics (TENX) Income from Continuing Operations (2016 - 2017)

Tenax Therapeutics' Income from Continuing Operations history spans 8 years, with the latest figure at 17029573.0 for Q4 2017.

  • For Q4 2017, Income from Continuing Operations rose 71.41% year-over-year to 17029573.0; the TTM value through Dec 2017 reached 9205898.0, up 87.63%, while the annual FY2025 figure was 52566000.0, 198.62% down from the prior year.
  • Income from Continuing Operations for Q4 2017 was 17029573.0 at Tenax Therapeutics, down from 1310420.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 3498886.0 in Q1 2017 and bottomed at 59564262.0 in Q4 2016.
  • The 5-year median for Income from Continuing Operations is 4671235.0 (2016), against an average of 11089650.0.
  • The largest annual shift saw Income from Continuing Operations crashed 105.91% in 2013 before it skyrocketed 164.53% in 2017.
  • A 5-year view of Income from Continuing Operations shows it stood at 2413277.0 in 2013, then crashed by 414.91% to 12426185.0 in 2014, then plummeted by 89.11% to 23499397.0 in 2015, then plummeted by 153.47% to 59564262.0 in 2016, then surged by 71.41% to 17029573.0 in 2017.
  • Per Business Quant, the three most recent readings for TENX's Income from Continuing Operations are 17029573.0 (Q4 2017), 1310420.0 (Q3 2017), and 3014369.0 (Q2 2017).